Gene Therapy Market Heats up as Sarepta Buys Myonexus for $165 Million

As part of the deal, Sarepta picks up five gene therapy candidates to treat distinct types of limb-girdle muscular dystrophy (LGMD). The original deal was inked in May 2018, when the two companies agreed to partner to develop Myonexus’ five LGMD gene therapy compounds.